Trinity Capital Inc. Provides $35 Million in Growth Capital to Monteris Medical to Support Neurosurgical Technology Advancements
MWN-AI** Summary
Trinity Capital Inc. (Nasdaq: TRIN), a prominent alternative asset manager, recently announced a commitment of $35 million in growth capital to Monteris Medical, a MedTech company specializing in minimally invasive neurosurgical technologies. This funding aims to facilitate the commercialization of Monteris' flagship product, the NeuroBlate System, which utilizes a robotically controlled laser interstitial thermal therapy (LITT) platform for the removal of abnormal brain tissues. Employing MRI-guided laser technology, the NeuroBlate System presents a less invasive alternative to traditional open neurosurgery, offering the potential for lower complication rates and shorter hospital stays for patients.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expressed his enthusiasm for Monteris' innovative approach, highlighting its role in expanding treatment options within the neurosurgery sector. The financing is anticipated to bolster Monteris Medical's clinical research programs and overall growth strategy. Martin J. Emerson, President and CEO of Monteris Medical, emphasized that the partnership with Trinity Capital, alongside support from Series E equity investors, strengthens the company's capacity to accelerate growth and innovate in minimally invasive neurosurgical procedures.
Trinity Capital focuses on providing tailored debt solutions across several lending verticals, including Life Sciences, and has effectively deployed over $5.5 billion across 463 investments since its inception in 2008. The firm is headquartered in Phoenix, Arizona, and has a strategic presence across the U.S. and Europe.
Monteris Medical is known for its pioneering work in MR-guided laser ablation systems, which have been shown to deliver effective outcomes for patients with brain tumors and epilepsy. The company’s technology, supported by clinical studies, reflects a growing trend towards minimally invasive surgical interventions in the field of neurosurgery.
MWN-AI** Analysis
Trinity Capital Inc. (Nasdaq: TRIN) has recently made headlines by committing $35 million in growth capital to Monteris Medical, a prominent player in the MedTech field specializing in minimally invasive neurosurgical technology. This investment not only underscores Trinity Capital's strategic focus on supporting innovative health solutions but also presents a significant opportunity for investors looking to capitalize on growth in the flourishing life sciences sector.
Monteris Medical's NeuroBlate System is groundbreaking, employing MRI-guided laser technology for interstitial thermal therapy to treat conditions such as brain tumors and drug-resistant epilepsy. The promise of fewer complications and shorter recovery times positions NeuroBlate as a compelling alternative to traditional surgery, offering potential for widespread adoption among leading healthcare providers.
For investors considering Trinity Capital, this partnership reflects an attractive investment in a high-growth vertical. The life sciences sector has consistently demonstrated resilience and potential for robust returns, especially in the wake of ongoing healthcare innovations post-pandemic. Trinity's commitment to fostering companies like Monteris, which is aligned with evolving patient needs and technological advancements, positions it as a forward-thinking investment choice.
Moreover, Trinity Capital's established track record—having deployed over $5.5 billion across more than 463 investments since inception—suggests a well-structured risk management approach. The company’s diverse lending verticals across various asset classes, including life sciences, provide a balanced portfolio, mitigating risks while maximizing returns.
Investors keen on taking advantage of Trinity Capital’s growth potential should evaluate the company’s financial health, market positioning, and operational strategies, especially in light of this recent investment in Monteris Medical. The healthcare landscape continues to evolve, and investments in companies that are innovative and provide essential solutions are likely to yield substantial returns over time.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
PHOENIX, March 12, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading international alternative asset manager, today announced the commitment of $35 million in growth capital to Monteris Medical ("Monteris"), a MedTech company specializing in minimally invasive neurosurgical technology.
Monteris Medical develops and commercializes the NeuroBlate System, a robotically controlled laser interstitial thermal therapy (LITT) platform that uses MRI-guided laser technology to remove abnormal brain tissue. The system features robotic-controlled, precise, laser energy delivery that is used to treat brain tumors, radiation necrosis, and drug-resistant epilepsy. The NeuroBlate system is designed to provide a minimally invasive alternative to traditional open neurosurgery, with the goal of helping patients experience lower complication rates and shorter hospital stays.
"We believe Monteris is advancing innovation across the life sciences sector with technology that is expanding treatment options in neurosurgery," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. "We are proud to support a team that is not only pushing the boundaries of medical technology, but also delivering meaningful new treatment options for patients."
The growth capital will help support Monteris Medical's commercialization of the Neuroblate System and expansion of clinical research programs.
"Securing this new credit facility from Trinity Capital, alongside the support of our Series E equity investors, strengthens our ability to accelerate growth and continue delivering innovative, minimally invasive neurosurgical solutions for patients in need," said Martin J. Emerson, President and CEO of Monteris Medical. "Trinity's partnership reflects strong confidence in our strategy, the NeuroBlate System, and the expanding clinical impact our technology is making across leading neuroscience centers. This financing ensures we can further invest in commercial expansion, product innovation, and the teams who bring our mission to life every day."
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).
About Monteris and the NeuroBlate® System
Monteris Medical develops and markets innovative, MR?guided laser ablation systems that enable minimally invasive, robotically controlled brain surgery, often referred to as laser ablation, LITT (laser interstitial thermal therapy) or SLA (stereotactic laser ablation). The company's NeuroBlate System is designed for adults and children aged two and older and uses laser technology to precisely destroy abnormal brain tissue, including certain brain tumors and specific areas of the brain that cause seizures due to epilepsy. NeuroBlate is the only LITT platform with a robotic interface that supports the targeted, safe delivery of laser energy and is supported by published prospective clinical data. Multicenter studies on NeuroBlate show that patients typically experience short hospital stays, low rates of complications, improved quality of life and outcomes comparable to open surgical resection.
SOURCE Trinity Capital Inc.
FAQ**
How does the $35 million growth capital from Trinity Capital Inc. TRIN specifically enhance Monteris Medical's commercialization efforts for the NeuroBlate System amidst a competitive MedTech landscape?
What are the anticipated clinical outcomes of the NeuroBlate System that Trinity Capital Inc. TRIN expects to impact significantly through its investment in Monteris Medical?
In what ways will Trinity Capital Inc. TRIN's investment influence the expansion of Monteris Medical's clinical research programs and product innovations?
How does Trinity Capital Inc. TRIN assess the risks and potential returns associated with financing companies in the life sciences sector, such as Monteris Medical?
**MWN-AI FAQ is based on asking OpenAI questions about Trinity Capital Inc. (NASDAQ: TRIN).
NASDAQ: TRIN
TRIN Trading
-1.28% G/L:
$14.535 Last:
468,659 Volume:
$14.58 Open:
